No second PI for 10x against NanoString, UPC rules
Managing IP is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

No second PI for 10x against NanoString, UPC rules

Munich.jpg
Munich

Judge Matthias Zigann said the panel wasn’t convinced that NanoString had infringed the 10x Genomics patent

The Unified Patent Court refused to grant a second preliminary injunction for 10x Genomics against rival biotech company NanoString in Munich today, October 10.

Presiding judge Matthias Zigann said the panel was unconvinced that NanoString had infringed 10x’s patent.

The judge said the panel’s findings on infringement and validity were not prejudicial on the main proceedings.

10x won the first full PI hearing in the court’s history last month over a separate but related patent. That ruling meant NanoString cannot sell its allegedly infringing products in 17 European countries while proceedings are ongoing.

The lawsuit concerns NanoString’s CosMx Spatial Molecular Imager device and CosMx reagents for RNA detection.

10x claimed NanoString infringed patents related to Xenium, the company’s own RNA analysis tool that it launched in December 2022.

There is parallel litigation between the parties at the US District Court for the District of Delaware, where 10x has also filed two infringement lawsuits.

Trials have been scheduled in Delaware in November 2023 and September 2024.

NanoString has argued that 10x’s technology was originally developed at Harvard University with grant funding from the US National Institutes of Health, with the intention it would be made widely available via licensing.

Harvard exclusively licensed the technology to ReadCoor, which was acquired by 10x in 2020.

“In contrast with the promises made in the grant application, 10x is now using the acquired ReadCoor patents in lawsuits designed to reduce the scientific community’s access to innovative technologies intended for broad access,” NanoString has claimed.

Germany’s Federal Patent Court has also issued a preliminary opinion in which it found the claims of one of 10x’s key patents to be valid. An oral hearing has been scheduled for May 2024.

The Munich Regional Court, meanwhile, granted an injunction in favour of 10x in May this year. NanoString has appealed against that ruling to the Higher Regional Court.

10x may yet appeal the latest UPC ruling. The UPC has yet to schedule a date for a trial on the merits of the case.

more from across site and ros bottom lb

More from across our site

A team of lawyers who joined Norton Rose Fulbright from Polsinelli say they were drawn to the firm's global platform
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Lawyers say a ruling concerning liability for trademark infringement could give company directors an easy way out and create litigation uncertainty
The LMG Life Sciences Awards announces the winners for the 5th annual awards
Some US lawyers have strengthened their connections with European firms as they help clients determine whether the UPC will become a 'centre of gravity'
In the latest episode, the team discusses the battle to take control of listed company and IP business Qantm IP, and looks at some recent hiring trends
To mark Mental Health Awareness Week, lawyers explain how they manage their mental health, and how they pluck up the courage to ask themselves difficult questions
IP lawyers unpick a case heard at the CJEU’s Grand Chamber this week that could potentially create a new world for litigation in Europe
A lawyer who replied to a cease-and-desist letter with just two words has shown others how to deal with vexatious infringement allegations
The suggested rule change surrounding terminal disclaimers could ease the burden on defendants, but risks complicating prosecution strategies
Gift this article